CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 210 enrolled
Drug / intervention
Modafinil +1 moredrug
Likely dose
Modafinil 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00520286
NCT00520286Phase 2Completed
CompareCT.gov

Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence

National Institute on Drug Abuse (NIDA)·interventional·Posted Aug 24, 2007·Updated Apr 7, 2017

In Brief

A Phase 2 clinical trial evaluating Modafinil and Placebo for Methamphetamine Dependence. Completed, enrolled 210 participants across 8 sites.

Detailed Summary

The purpose of this study will be to examine the safety and efficacy of modafinil in increasing number of methamphetamine non-use weeks in subjects with methamphetamine dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Dependence
CountriesUnited States
CollaboratorsVA Office of Research and Development

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.9 years ago

Interventions

Modafinildrug

200 mg or 400 mg /daily

Placebodrug

Placebo / daily